Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP

Y. Dauvilliers (Montpellier, France), C. CAUSSE (Paris, France), J. Verbraecken (Antwerp, Belgium), M. Partinen (Helsinki, Finland), J. Hedner (Göteborg, Sweden), T. Saaresranta (Turku, Finland), O. Georgev (Sofia, Bulgaria), R. Tiholov (Kozloduy, Bulgaria), I. Lecomte (Paris, France), R. Tamisier (Grenoblenoble, France), P. Levy (Grenoble, France), J. Lecomte (Paris, France), J. Schwartz (Paris, France), J. Pépin (Grenoble, France)

Source: Sleep and Breathing Conference 2021
Session: Treatment and management of sleep respiratory diseases
Session type: Oral Presentation
Number: 0
Disease area: Sleep and breathing disorders

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Dauvilliers (Montpellier, France), C. CAUSSE (Paris, France), J. Verbraecken (Antwerp, Belgium), M. Partinen (Helsinki, Finland), J. Hedner (Göteborg, Sweden), T. Saaresranta (Turku, Finland), O. Georgev (Sofia, Bulgaria), R. Tiholov (Kozloduy, Bulgaria), I. Lecomte (Paris, France), R. Tamisier (Grenoblenoble, France), P. Levy (Grenoble, France), J. Lecomte (Paris, France), J. Schwartz (Paris, France), J. Pépin (Grenoble, France). Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP. Sleep and Breathing Conference 2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP.
Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing
Year: 2021


Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP.
Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing
Year: 2021



Effects of long term nCPAP treatment on patients with obstructive sleep apnoea syndrom
Source: Eur Respir J 2007; 30: Suppl. 51, 322s
Year: 2007

CPAP variability in long term follow-up of OSAS (obstructive sleep apnea syndrome) patients
Source: Eur Respir J 2006; 28: Suppl. 50, 412s
Year: 2006

CPAP treatment for obstructive sleep apnoea syndrome after CPAP training term
Source: Eur Respir J 2002; 20: Suppl. 38, 102s
Year: 2002

Auto-titrating CPAP for treating obstructive sleep apnoea, a bimodal response in males?
Source: Eur Respir J 2006; 28: Suppl. 50, 409s
Year: 2006

Return of sleep apnoea and sleep fragmentation following CPAP withdrawal in patients with obstructive sleep apnoea
Source: Eur Respir J, 53 (5) 1802351; 10.1183/13993003.02351-2018
Year: 2019



The effect of CPAP treatment on Galectin-3 level in patients with severe obstructive sleep apnea
Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing
Year: 2018


Daytime hypoxemia in obstructive sleep apnoea (OSA) subjects before CPAP therapy
Source: Annual Congress 2009 - Clinical aspects of sleep apnoea
Year: 2009

Role of CPAP treatment in elderly with moderate obstructive sleep apnea
Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects
Year: 2019


Hypercapnia and respiratory drive in obstructive sleep apnoea patients before and after CPAP treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 103s
Year: 2002

Long-term CPAP compliance in women with obstructive sleep apnoea
Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health
Year: 2012


Does personality change in obstructive sleep apnea (OSA) patients using CPAP?
Source: Eur Respir J 2006; 28: Suppl. 50, 409s
Year: 2006

Reported but not measured sleep latency predicts successful CPAP therapy in patients with obstructive sleep apnoea
Source: Eur Respir J 2002; 20: Suppl. 38, 101s
Year: 2002

Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients?
Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases
Year: 2006


PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment
Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing
Year: 2012

Pitolisant efficacy in excessive daytime sleepiness for patients with obstructive sleep apnea
Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing
Year: 2021


Pitolisant efficacy in excessive daytime sleepiness for patients with obstructive sleep apnea
Source: Sleep and Breathing Conference 2021
Year: 2021



Treatment with CPAP reduces mortality in patients with obstructive sleep apnoea syndrome within less than 3 years
Source: Annual Congress 2006 - Therapeutic effects in obstructive sleep apnoea
Year: 2006


Cardiovascular regulation effects of CPAP therapy in obstructive sleep apnea patients with and without hypertension during daytime
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II
Year: 2012